IP Library › Granted Patent US 8,993,319
Granted Patent B2
US 8,993,319 · App. 11/720,553 · Granted Mar 31, 2015

Monoclonal antibodies against NKG2A

Inventors: Alessandro Moretta (Genoa, IT); Emanuela Marcenaro (Genova-Pegli, IT); Francois Romagne (La Ciotat, FR); Pascale Andre (Marseilles, FR)
Assignees: Innate Pharma S.A.; University of Genova
C07K16/2851A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,319
App. No.
11/720,553
Granted
Mar 31, 2015
Kind
B2
Abstract

The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

Claims (1)

1. A hybridoma deposited at the CNCM under accession number I-3549.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2007
From: MORETTA, ALESSANDRO; MARCENARO, EMANUELA
To: UNIVERSITY OF GENOVA; INNATE PHARMA, S. A.
Reel/Frame 019723/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2007
From: ROMAGNE, FRANCOIS; ANDRE, PASCALE
To: INNATE PHARMA S.A.
Reel/Frame 019723/0052 →
Continuity (3)
Provisional Application 60639465 · Dec 28, 2004
Provisional Application 60639832 · Dec 28, 2004
Related Publication 20090208416A1 · Aug 20, 2009